Translation in Data Mining to Advance Personalized Medicine for Health Equity.

Personalized medicine is the development of 'tailored' therapies that reflect traditional medical approaches, with the incorporation of the patient's unique genetic profile and the environmental basis of the disease. These individualized strategies encompass disease prevention, diagnosis, as well as treatment strategies. Today's healthcare workforce is faced with the availability of massive amounts of patient- and disease-related data. When mined effectively, these data will help produce more efficient and effective diagnoses and treatment, leading to better prognoses for patients at both the individual and population level. Designing preventive and therapeutic interventions for those patients who will benefit most while minimizing side effects and controlling healthcare costs, requires bringing diverse data sources together in an analytic paradigm. A resource to clinicians in the development and application of personalized medicine is largely facilitated, perhaps even driven, by the analysis of "big data". For example, the availability of clinical data warehouses is a significant resource for clinicians in practicing personalized medicine. These "big data" repositories can be queried by clinicians, using specific questions, with data used to gain an understanding of challenges in patient care and treatment. Health informaticians are critical partners to data analytics including the use of technological infrastructures and predictive data mining strategies to access data from multiple sources, assisting clinicians' interpretation of data and development of personalized, targeted therapy recommendations. In this paper, we look at the concept of personalized medicine, offering perspectives in four important, influencing topics: 1) the availability of 'big data' and the role of biomedical informatics in personalized medicine, 2) the need for interdisciplinary teams in the development and evaluation of personalized therapeutic approaches, and 3) the impact of electronic medical record systems and clinical data warehouses on the field of personalized medicine. In closing, we present our fourth perspective, an overview to some of the ethical concerns related to personalized medicine and health equity.

[1]  M. West,et al.  Embracing the complexity of genomic data for personalized medicine. , 2006, Genome research.

[2]  G. Kuo,et al.  HLA-B*5701 testing to predict abacavir hypersensitivity , 2010, PLoS currents.

[3]  F J Trevor Burke,et al.  Practice-based research. , 1997, Journal of the American Dental Association.

[4]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.

[5]  Eliminating Racial,et al.  COMMITTEE ON UNDERSTANDING AND ELIMINATING RACIAL AND ETHNIC DISPARITIES IN HEALTH CARE , 2003 .

[6]  Mph Michael M. Ward MD Personalized Therapeutics: A Potential Threat to Health Equity , 2012, Journal of General Internal Medicine.

[7]  The High Concentration of U.S. Health Care Expenditures , 2006 .

[8]  J. Henry,et al.  Adoption of Electronic Health Record Systems among U . S . Non-Federal Acute Care Hospitals : 2008-2015 , 2013 .

[9]  S. Bates,et al.  Progress towards personalized medicine. , 2010, Drug discovery today.

[10]  Jan Schultz A history of the promis technology: an effective human interface , 1988, A History of Personal Workstations.

[11]  G. Ginsburg,et al.  The path to personalized medicine. , 2002, Current opinion in chemical biology.

[12]  Isaac S. Kohane,et al.  Architecture of the Open-source Clinical Research Chart from Informatics for Integrating Biology and the Bedside , 2007, AMIA.

[13]  Adrienne Y. Stith,et al.  Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care , 2005 .

[14]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[15]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[16]  J. Westfall,et al.  Practice-based research--"Blue Highways" on the NIH roadmap. , 2007, JAMA.

[17]  Incorporating translational research with clinical research to increase effectiveness in healthcare for better health , 2014, Clinical and Translational Medicine.

[18]  Eliza Strickland Their prescription: big data , 2015, IEEE Spectrum.

[19]  D. Blumenthal Launching HITECH. , 2010, The New England journal of medicine.

[20]  Leslie Z. Benet,et al.  The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.

[21]  Jan Schultz A history of the Promis technology: an effective human interface , 1986, HPW '86.

[22]  D. Stoff,et al.  Moving toward paradigm-shifting research in health disparities through translational, transformational, and transdisciplinary approaches. , 2010, American journal of public health.

[23]  W. Frontera,et al.  A Multiinstitutional, Multidisciplinary Model for Developing and Teaching Translational Research in Health Disparities , 2011, Clinical and translational science.

[24]  Russ B. Altman,et al.  Bioinformatics challenges for personalized medicine , 2011, Bioinform..

[25]  John-Michael Sauer,et al.  Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[26]  Alla Katsnelson,et al.  Momentum grows to make 'personalized' medicine more 'precise' , 2013, Nature Medicine.

[27]  K. Wade,et al.  Practice-Based Research , 2007, Social work in health care.

[28]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[29]  P. Conway,et al.  The "3T's" road map to transform US health care: the "how" of high-quality care. , 2008, JAMA.

[30]  L. Hood,et al.  A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. , 2012, New biotechnology.

[31]  George W. Bush Promoting Innovation and Competitiveness: President Bush's Technology Agenda , 2002 .